Hemorrhoid Treatment Market Growth Opportunities in Ambulatory Surgical Centers

1. Hemorrhoid Treatment Market Forecast 2032: New Drug Approvals and Clinical Trials The hemorrhoid treatment market addresses both mild and severe anal vein disorders through over-the- counter (OTC) creams, ointments, and minimally invasive procedures like rubber band ligation, sclerotherapy, and infrared coagulation. Growth is driven by the high prevalence of hemorrhoids— particularly among the elderly and those with sedentary lifestyles—and rising consumer awareness. OTC product availability and convenient access via pharmacies and online platforms have also contributed to market expansion. Ongoing innovations, including faster-acting formulations and advanced minimally invasive devices, support broader adoption. As stigma around the condition decreases and treatment- seeking rises, the market is well-positioned for steady global growth. According to Fortune Business Insights, the global hemorrhoid treatment market was valued at USD 1.03 billion in 2023. The market is projected to grow from USD 1.08 billion in 2024 to USD 1.74 billion by 2032, exhibiting a CAGR of 6.1% during the forecast period. In 2023, North America dominated the hemorrhoid treatment market with a market share of 44.66%. Top Companies in the Market           Lupin (India) Cipla (India) AMATO PHARMACEUTICAL PRODUCTS, LTD. (Japan) Church & Dwight Co., Inc. (U.S.) Haleon Group of Companies (U.K.) Sebela Pharmaceuticals (U.S.) Bayer AG (Germany) Sanofi (France) Abbott (U.S.) Sun Pharmaceutical Industries, Inc. (India) Key Industry Development In September 2024, Haleon Group agreed to acquire Tianjin TSKF Pharmaceutical Co. Ltd. in China to enhance strategic and operational control, strengthening its position in the hemorrhoid treatment market. Market Drivers & Restraints Market Drivers Growing Disease Prevalence: Hemorrhoids affect an estimated 4.4% of the global population, with higher rates among the elderly. Risk factors such as sedentary lifestyles, obesity, and chronic constipation have driven an increasing need for both OTC and prescription treatments. Availability of OTC Treatments: Over-the-counter hemorrhoid drugs—widely available in pharmacies and online—have fueled market growth. Notably, in March 2024, Karo Healthcare obtained exclusive rights to market Proctosedyl OTC in Italy, demonstrating how OTC access enhances regional adoption. Market Restraints

2. Social Stigma: Embarrassment and hesitation to discuss or seek treatment for hemorrhoids remain major barriers. A study in Saudi Arabia cited 66.5% of respondents avoiding medical consultation due to stigma. Alternative Procedures: Non-pharmacological interventions—like rubber band ligation and sclerotherapy— offer effective results, reducing reliance on topical therapies and impacting pharmaceutical market growth. Regulatory Hurdles: Hemorrhoids lack FDA-approved pharmaceutical remedies, meaning strict regulatory protocols slow drug development and market entry. Market Trends & Opportunities R&D and clinical pipeline activity are increasing—highlighted by Citius Pharmaceuticals’ Phase 2b trials of Halo-Lido (CITI-002), which combines treatment modes for enhanced symptom relief. Convenience-driven product innovation is accelerating, such as Haleon’s Preparation H Totables wipes, designed to offer rapid relief for itching and swelling. The rise of telemedicine is also transforming the market, enabling discreet treatment access Regulatory Landscape Hemorrhoid treatments are regulated by the FDA and EMA, requiring clinical testing, manufacturing compliance, and rigorous labeling—factors that shape launch timelines and competition. Market Segmentation By Product Type

3.    Creams & Ointments: Dominant segment due to ease of use and frequent consumer preference. Suppositories: Popular for internal hemorrhoids (grades I & II). Sprays & Others: Growing appeal for convenience and rectal application options. By Drug Class  Corticosteroids: Leading drug class with products like hydrocortisone creams reducing inflammation. Local Anesthetics: Offer temporary pain relief—brands like Germoloids in the UK with "Numb Your Bum" campaign. NSAIDs & Others: Stool softeners and other medications supporting symptomatic relief.   By Type (Internal vs External)   Internal Hemorrhoids: Command a significant market share, with grades I–IV. External Hemorrhoids: Expected to grow as patient awareness and treatment availability increase. By Distribution Channel  Drug Stores & Retail Pharmacies: Leading channel due to OTC product availability and self- treatment preference. Hospital Pharmacies: Serve patients needing prescription treatments after advanced diagnosis. Online Pharmacies: Fastest-growing channel, offering privacy and convenience via digital integration.   Regional Insights North America:Held the largest market share (~44.6%) with a value of USD 0.46 billion in 2023, backed by advanced healthcare systems and public awareness campaigns. Europe: Ranked second, driven by high disease incidence—e.g., Germany treating ~3.3 million patients annually—and supportive healthcare infrastructure. Asia Pacific: Fast-growing, propelled by rising healthcare access, urbanisation, and campaigns like India’s #Let’sTalkPiles initiative. Competitive Landscape Major market players include Haleon Group, Church & Dwight, Bayer AG, Sebela Pharmaceuticals, among others. Strategic moves—partnerships with local distributors (e.g., Church & Dwight & DKSH in Hong Kong)—support market reach and strength. Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/hemorrhoid-treatment-market-110985 Future Outlook & Recommendations The hemorrhoid treatment market is poised for sustained growth, addressing both medical and OTC segments. Key opportunities include:

4.     Development of convenient, rapid-acting formulations (like wipes and sprays). Pipeline investments that target core pathophysiology, such as CITI-002. Digital health tools—telemedicine and e-commerce—for accessible, discreet care. Patient-centric educational marketing to reduce stigma and promote early treatment. Industry collaboration with telehealth providers and expanded OTC outreach can further extend market penetration, especially in emerging regions with burdened healthcare systems. Conclusion With its expected growth from USD 1.03 billion to USD 1.74 billion by 2032 and CAGR of 6.1%, the hemorrhoid treatment market is on a steady upward trajectory. While challenges remain—from stigma to regulatory constraints—the future holds significant promise through innovation, convenience- driven therapies, and digital healthcare integration. Stakeholders who focus on patient-centric solutions, affordable OTC access, and targeted therapeutics are best positioned to drive market success. About Us: Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in. Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data. Contact us: Fortune Business Insights™ Pvt. Phone: USA: +1 833 909 2966 (Toll-Free), United Kingdom: +44 808 502 0280 (Toll-Free), APAC: +91 744 740 1245 Email: sales@fortunebusinessinsights.com